Home 
Bratislava Medical Journal 2021 Bratislava Medical Journal Vol.122, No.8, p.598–604,2021
Bratislava Medical Journal 2021 Bratislava Medical Journal Vol.122, No.8, p.598–604,2021
Journal info
|
||||
Select Journal
Journals
Bratislava Medical Journal 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 Ekologia - Ecology Endocrine Regulations General Physiology and Biophysics Neoplasma Acta Virologica Studia Psychologica Cardiology Letters Psychológia a patopsych. dieťaťa Kovove Materialy-Metallic Materials Slovenská hudba 2025Webshop Cart
Your Cart is currently empty.
Info: Your browser does not accept cookies. To put products into your cart and purchase them you need to enable cookies.
Bratislava Medical Journal Vol.122, No.8, p.598–604,2021 |
||
| Title: Evaluation of index of cardiac electrophysiological balance in COVID-19 patients | ||
| Author: R. Asoglu, H. Tibilli, E. Asoglu, N Aladag, M. Ozdemir, A. Suner | ||
| Abstract: AIM: The aim of the current study was to evaluate the index of Cardiac Electrophysiological Balance (iCEB) in hospitalized COVID-19 patients receiving Hydroxychloroquine / azithromycin (HCQ / AZ) combination therapy to determine the susceptibility to ventricular arrhythmia among these patients. METHOD: Sixty-seven COVID-19 patients admitted to the ward were included in the study. Electrocardiograms (ECGs) were obtained from all patients before the initiation of treatment and on treatment day 5. QT/QRS (iCEB) and QTc/QRS (iCEBc) ratios were calculated. RESULTS: QRS, QT and QTc intervals were significantly prolonged on day 5 measurements compared to pre-treatment period (p <0.05). Overall, mean iCEB was 3.6±0.4 before treatment and 3.8±0.4 on day 5 in the study population (p <0.001). Considering the iCEBc values, a significant increase was observed in patients receiving HCQ/AZ treatment compared to pre-treatment period (4.1±0.5 vs 4.4±0.6; p <0.001). CONCLUSIONS: To the best of our knowledge, this was the first study to investigate iCEB and iCEBc parameters in patients with COVID-19 on HCQ/AZ therapy. In this study, we demonstrated significantly increased iCEB and iCEBc values following HCQ/AZ treatment in COVID-19 patients. iCEB and iCEBc may serve as a noninvasive, simple, and novel biomarker for detecting increased pro-arrhythmia risk in COVID-19 patients (Tab. 3, Fig. 3, Ref. 36). |
||
| Keywords: COVID-19, index of Cardiac Electrophysiological Balance (iCEB), Hydroxychloroquine, azithromycin, ventricular arrhythmia | ||
| Published online: 20-Jul-2021 | ||
| Year: 2021, Volume: 122, Issue: 8 | Page From: 598, Page To: 604 | |
| doi:10.4149/BLL_2021_096 |
||
|
|
 download file |
|